FOR RESEARCH USE ONLY. The content provided in this article is for educational and informational purposes only and is based on published scientific literature. All compounds discussed are for research purposes only. Nothing in this article constitutes guidance on human or animal use. Restore Peptides does not endorse or encourage the use of these products outside of a controlled research setting.

Body Protection Compound-157 (BPC-157) is a synthetic pentadecapeptide derived from a protein isolated in human gastric juice. Since its initial characterization by Sikiric et al. in 1993, the compound has become one of the most frequently studied synthetic peptides in preclinical literature, with over 100 published studies spanning gastrointestinal, musculoskeletal, vascular, and neural experimental models.

Despite this volume of preclinical data, BPC-157 remains unapproved by the U.S. Food and Drug Administration for any indication, and the compound’s translational profile is constrained by the near-total absence of controlled human clinical trials. This article provides a mechanistic overview of BPC-157 preclinical research conducted in laboratory and animal models, examines the major signaling pathways identified in published literature, and outlines the critical limitations that define the current state of the field.

Key Takeaways

BPC-157 is a 15-amino-acid synthetic peptide originally isolated from human gastric juice and studied primarily in preclinical (in vitro and animal) models since the early 1990s.
Published research has identified multiple proposed signaling pathways, including VEGFR2-Akt-eNOS (angiogenesis), growth hormone receptor-JAK2 (connective tissue), FAK-paxillin (cell migration), and nitric oxide system modulation.
A 2025 systematic review of 36 studies found that 35 were preclinical animal models with only one clinical study meeting inclusion criteria, underscoring the compound’s early-stage research status.
The majority of published BPC-157 research originates from a single laboratory group, raising questions about independent reproducibility that the broader research community has noted.
No regulatory agency has approved BPC-157 for any human indication, and the FDA classifies it as a Category 2 bulk drug substance with identified safety concerns for compounding use.

Peptide Structure and Origin

BPC-157 (also designated PL 14736 or PL-10 in earlier literature) is a pentadecapeptide with the amino acid sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val and a molecular weight of 1,419.53 Da. The peptide is a partial sequence of a larger protein identified in human gastric juice known as Body Protection Compound.

Unlike the native protein, the synthetic pentadecapeptide fragment does not occur naturally in isolation and is produced through solid-phase peptide synthesis for laboratory use.

Research interest in BPC-157 originated from early observations in gastric mucosal models, where the peptide demonstrated cytoprotective effects in tissue exposed to various forms of experimentally induced damage.

These initial gastroprotective studies, conducted primarily at the University of Zagreb under Sikiric and colleagues, formed the foundation for subsequent investigations across multiple organ systems in animal models. All research peptides used in published BPC-157 studies are supplied as synthetic, lyophilized preparations for laboratory reconstitution.

VEGFR2-Akt-eNOS Pathway – Angiogenic Signaling

One of the most thoroughly characterized molecular interactions associated with BPC-157 involves the vascular endothelial growth factor receptor 2 (VEGFR2) signaling cascade. A 2017 study published in the Journal of Molecular Medicine by Hsieh et al. demonstrated that BPC-157 promoted VEGFR2 activation and internalization in human umbilical vein endothelial cells (HUVECs), with downstream phosphorylation of Akt and endothelial nitric oxide synthase (eNOS).

The investigators observed that BPC-157 treatment was associated with increased VEGFR2 expression at both the mRNA and protein levels, suggesting a mechanism through which the peptide may influence new vessel formation in controlled experimental settings.

Src-Cav-1-eNOS Pathway and Vasomotor Regulation

A subsequent 2020 study published in Scientific Reports by Hsieh et al. extended these findings by examining BPC-157’s effects on vasomotor tone in isolated aortic ring preparations. That investigation identified an additional mechanism involving disruption of the Caveolin-1 (Cav-1)–eNOS inhibitory complex, with BPC-157 reducing the interaction between these two proteins and promoting nitric oxide production in a dose-dependent manner through the Src-Cav-1-eNOS pathway.

These two studies represent the primary published evidence for BPC-157’s interaction with the VEGFR2 axis. Both were conducted in vitro using cell culture and isolated tissue models, and neither has been replicated in vivo in human subjects.

Growth Hormone Receptor and JAK2 Signaling

A separate line of investigation has examined BPC-157’s effects on growth hormone receptor (GHR) expression in connective tissue models. A 2014 study published in Molecules by Chang et al. used cDNA microarray analysis on rat Achilles tendon fibroblasts and identified GHR as one of the most significantly upregulated genes following BPC-157 exposure. The researchers demonstrated that BPC-157 increased GHR expression in a dose- and time-dependent manner at both the mRNA and protein levels.

The same study further showed that in fibroblasts pretreated with BPC-157, the addition of growth hormone activated the Janus kinase 2 (JAK2) signaling pathway to a greater degree than in untreated controls, with longer pretreatment periods corresponding to higher levels of phosphorylated JAK2.

The investigators also observed increased proliferating cell nuclear antigen (PCNA) expression and enhanced cell proliferation in MTT assays when growth hormone was added to BPC-157-pretreated fibroblasts.

This study provides a proposed mechanistic link between BPC-157 and growth factor signaling in connective tissue cells. However, the findings are limited to a single in vitro fibroblast model and have not been independently confirmed in additional tissue types or by other research groups.

FAK-Paxillin Signaling and Cell Migration Models

Focal adhesion kinase (FAK) and paxillin phosphorylation have been identified as additional intracellular targets associated with BPC-157 exposure in cell migration experiments. Published studies on tendon fibroblasts and skeletal muscle cells have reported that BPC-157 treatment increased phosphorylation of FAK and paxillin – two proteins central to the focal adhesion complex that regulates cell adhesion, spreading, and migration.

In skeletal muscle cell models, researchers observed that BPC-157 enhanced cell migration and spreading with concurrent upregulation of paxillin and vinculin expression, suggesting that the peptide’s observed effects on cellular motility may involve focal adhesion complex assembly.

The FAK-paxillin cascade is a well-established signaling node in cell biology, where activated FAK recruits Src kinase at focal adhesion sites to form a FAK-Src complex that phosphorylates downstream adapter proteins including paxillin, activating pathways that regulate cytoskeletal reorganization.

These findings are consistent with the broader pattern of BPC-157 research, where multiple signaling pathways have been implicated in controlled in vitro settings without corresponding in vivo human validation.

Nitric Oxide System Modulation

BPC-157’s interaction with the nitric oxide (NO) system has been a recurring theme across multiple experimental paradigms. Research from the Sikiric group has described what they characterize as a modulatory – rather than unidirectional – relationship between BPC-157 and NO production. In models of NO deficiency (such as L-NAME-induced NOS blockade), BPC-157 was associated with increased NO bioavailability; in models of excessive NO production (such as L-arginine overdose), BPC-157 was associated with reduced pathological NO overproduction.

This bidirectional interaction with the NO system has been proposed as a unifying mechanism underlying many of the peptide’s observed effects across different experimental models, though the precise molecular mechanism by which BPC-157 achieves this modulation remains incompletely characterized. The NO system findings have been described across multiple publications from the same research group, and independent confirmation of the proposed modulatory mechanism from other laboratories remains limited.

Gastrointestinal and Mucosal Models

The original research context for BPC-157 was gastrointestinal cytoprotection, and this remains one of the most extensively studied experimental domains for the peptide. Published studies using animal models have described BPC-157’s effects in contexts including experimentally induced gastric ulcers, inflammatory bowel disease models, NSAID-induced gastrointestinal injury, various gastrointestinal fistula models, and anastomotic site repair models.

Sikiric and colleagues have framed these gastroprotective effects within the concept of “Robert’s cytoprotection” – a pharmacological paradigm in which certain compounds protect mucosal tissue against damage through mechanisms independent of acid secretion reduction. The group has published extensively on BPC-157’s ability to maintain mucosal integrity under conditions that normally produce significant tissue damage in animal models.

A 2025 abstract presented at the American College of Gastroenterology meeting reviewed BPC-157’s preclinical gastrointestinal data, noting the compound’s effects across multiple GI injury models while acknowledging the absence of controlled human clinical data in gastroenterology.

Musculoskeletal Models – Systematic Review Evidence

The most comprehensive synthesis of BPC-157 preclinical literature to date is a 2025 systematic review by Vasireddi et al. published in HSS Journal (the journal of the Hospital for Special Surgery). The review examined English-language literature from database inception through June 2024, screening 544 articles from PubMed, Cochrane, and Embase. After applying inclusion and exclusion criteria, 36 articles were retained: 21 reporting on mechanism of action, 15 on musculoskeletal outcomes, 3 on metabolism, and 4 on safety.

Review Outcomes and Evidence Gaps

Of the 36 included studies, 35 were preclinical animal models and only one was a clinical study – a ratio that starkly illustrates the compound’s early research status.

The review reported that in preclinical models, BPC-157 was associated with improved functional, structural, and biomechanical outcomes in muscle, tendon, ligament, and bone injury models. These musculoskeletal studies used various animal injury models including Achilles tendon transection, medial collateral ligament transection, quadriceps muscle crush injury, and segmental bone defects.

The systematic review concluded that while preclinical evidence is broadly supportive, the near-total absence of human clinical data represents a critical gap that prevents any extrapolation beyond the animal model context.

Known Limitations and Research Gaps

Several significant limitations define the current state of BPC-157 research, and any assessment of the existing literature must account for these factors.

Single-laboratory concentration of research. The majority of published BPC-157 studies – estimated at over 80% of indexed records – originate from a single research group at the University of Zagreb led by Predrag Sikiric. While the group’s prolific output has generated substantial preclinical data, the scientific community has noted the need for broader independent replication.

Independent investigations from groups in Taiwan (Hsieh et al., Chang et al.) have corroborated some mechanistic findings, particularly regarding the VEGFR2 and GHR pathways, but the overall evidence base remains disproportionately concentrated.

Clinical Data Gaps and Regulatory Status

Near-absence of human clinical data. As of 2026, only three pilot studies have examined BPC-157 in human subjects: one investigating intraarticular administration for knee-related endpoints, one examining interstitial cystitis endpoints, and one assessing intravenous safety and pharmacokinetics. None of these represent the large-scale, randomized controlled trials necessary to establish clinical efficacy or comprehensive safety profiles.

A Phase I clinical trial (NCT02637284) sponsored by PharmaCotherapia was designed to be the first rigorous human safety study but was cancelled in 2016 with no data ever published.

Regulatory classification. The FDA classifies BPC-157 as a Category 2 bulk drug substance, a designation indicating identified safety concerns when used in compounding. The U.S. Anti-Doping Agency (USADA) lists BPC-157 as a prohibited substance. These regulatory positions reflect the absence of clinical safety and efficacy data rather than specific evidence of harm, but they underscore the compound’s status as a research-only compound.

Translational Barriers and Publication Bias

Translational uncertainty. Preclinical results in rodent models do not reliably predict outcomes in human physiology. Differences in metabolism, bioavailability, immune response, and pharmacokinetics between species represent well-established barriers to translation. Without comprehensive human pharmacokinetic data, fundamental questions about BPC-157’s absorption, distribution, metabolic fate, and potential for adverse interactions remain unanswered.

Publication bias considerations. The existing literature is heavily weighted toward positive findings, with limited reporting of negative or null results. A 2025 narrative review published in Cureus titled “Regeneration or Risk?” specifically addressed this concern, noting the absence of well-designed adverse event reporting in the preclinical literature.

Where BPC-157 Preclinical Research Stands Today

BPC-157 occupies an unusual position in peptide research – a compound with a substantial volume of preclinical literature but minimal clinical validation. The proposed mechanisms identified across published studies – VEGFR2-Akt-eNOS signaling, GHR-JAK2 pathway activation, FAK-paxillin-mediated cell migration, and NO system modulation – represent testable hypotheses that have been demonstrated in controlled in vitro and animal model conditions. The 2025 systematic review provides the most rigorous synthesis of this evidence to date, confirming broad preclinical support while explicitly identifying the critical need for human clinical trials.

For the research community, BPC-157 represents a compound where the gap between preclinical investigation and clinical evidence remains wide. The concentration of published research within a single laboratory group, the cancellation of the only registered Phase I trial, and the regulatory concerns identified by the FDA and USADA collectively underscore that BPC-157’s research profile is still in its early stages.

Future well-designed, independently conducted human studies will be necessary to determine whether preclinical observations translate meaningfully beyond the animal model context.

Researchers sourcing peptides for laboratory use can learn more about quality verification standards and purity documentation in our guide to understanding certificates of analysis

Frequently Asked Questions

What is BPC-157 and where does it originate?

BPC-157 is a synthetic 15-amino acid peptide (molecular weight 1,419.53 Da) derived from a partial sequence of Body Protection Compound, a protein isolated from human gastric juice. First characterized by Sikiric et al. in 1993, it does not occur naturally in isolation and is produced via solid-phase peptide synthesis for research purposes only.

What signaling pathways have been associated with BPC-157 in published research?

Preclinical studies have identified several proposed pathways, including VEGFR2-Akt-eNOS (angiogenic signaling), growth hormone receptor-JAK2 (tendon fibroblast models), FAK-paxillin focal adhesion cascade (cell migration), and bidirectional nitric oxide modulation. All findings derive from in vitro or animal model experiments and have not been validated in human clinical trials.

How extensive is the human clinical data on BPC-157?

Extremely limited. As of 2026, only three pilot studies have examined BPC-157 in human subjects. A Phase I trial (NCT02637284) was registered but cancelled in 2016 without publishing data. No large-scale randomized controlled trials have been conducted, and the compound is not FDA-approved for human use.

Why does the concentration of research in a single laboratory matter?

Over 80% of indexed BPC-157 publications originate from a single group at the University of Zagreb. Scientific consensus generally requires independent replication by multiple laboratories. Some independent confirmation has emerged from groups in Taiwan, but the evidence base remains disproportionately concentrated in one center.

What is BPC-157’s current regulatory status?

The FDA classifies BPC-157 as a Category 2 bulk drug substance, indicating identified safety concerns in compounding. USADA lists it as a prohibited substance. It is not approved for any human therapeutic indication by any regulatory agency and is available as a research peptide for in vitro and preclinical laboratory use only.

References

Sikiric, P., et al. (1993). A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. Journal of Physiology (Paris), 87(5), 313–327.
Hsieh, M.J., et al. (2017). Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine, 95(3), 323–333. https://pubmed.ncbi.nlm.nih.gov/27847966/
Hsieh, M.J., et al. (2020). Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Scientific Reports, 10, 17317. https://www.nature.com/articles/s41598-020-74022-y
Chang, C.H., et al. (2014). Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules, 19(11), 19066–19077. https://pubmed.ncbi.nlm.nih.gov/25415472/
Vasireddi, N., et al. (2025). Emerging use of BPC-157 in orthopaedic sports medicine: A systematic review. HSS Journal. https://pubmed.ncbi.nlm.nih.gov/40756949/
Józwiak, M., et al. (2025). Multifunctionality and possible medical application of the BPC 157 peptide – literature and patent review. Pharmaceuticals, 18(2), 185. https://www.mdpi.com/1424-8247/18/2/185
Sikiric, P., et al. (2025). BPC 157 therapy: Targeting angiogenesis and nitric oxide’s cytotoxic and damaging actions. Pharmaceuticals, 18(10), 1451. https://pmc.ncbi.nlm.nih.gov/articles/PMC12567428/

BPC-157 in Preclinical Research – Study Models, Proposed Mechanisms, and Known Limitations